Funding Rounds
Epsilogen

Epsilogen November 2018 Series A Funding Round

Epsilogen

Developer of immunoglobulin E (IgE) antibodies to treat cancer.

View Company Profile

GET THE TOP 10 COMPANIES OF THE WEEK IN YOUR EMAIL, EVERY TUESDAY.

OR DOWNLOAD OUR DATABASE OF 17,000 COMPANIES →

Summary

Stage: Series A

Raised Amount: $6.30M

Raised Date: 2018-11-30

Investors